ESOncology
#ESOambassador
#meeting #workingGroup
Daniela Shveid Gerson Gordana Petkovska Joana Marinho Ana Vasileva anja kovač
Fedro Peccatori MD, PhD

10 days to Xmas🎄....and less than 4 weeks to #GI 24 ASCO 🙌
Here are the key #GI #abstracts I am waiting for👇
Special Mentions
🌟NETTER2 - Dr. Simron Singh🇨🇦 #NET
🌟COBRA (NRG GI-005) - Van Morris, MD
CCTG Howie #CRCsm #ctDNA
Congrats to #GI 24 planning…

Happy Holidays!!! from our Centro Médico ABC Oncology Family 🦀 🇲🇽 🎄

2023 was an outstanding year for breast cancer research
As we start wrapping up #SABCS23 , we need to think about how to incorporate what we learned in the clinic and future research.
Looking forward to what is yet to come to improve outcomes for our patients!
OncoAlert #BCSM

Así se vivió el curso corto de actualización de genética y genómica para el oncólogo. ¡Agradecemos a todos los asistentes!
.
.
#smeo #sociedadmexicanadeoncología #médicosoncólogos #genéticaygenómica #oncology #oncología #cursocorto

Day 1 #ESMO23 Highlights #CommunityOncology

NSCLS
1. #CM816 Mark Awad

2. #KN671 Jonathan Spicer MD PhD

3. #ATTLAS

Breast Ca
4. #MonarchE #bcsm

5. #KN756 / #CM7FL Sherene Loi, MD

6. #KN522 TNBC Javier Cortes MD PhD

#lcsm #OncTwitter ESMO - Eur. Oncology #OncEd OncoAlert Stephanie Graff, MD, FACP, FASCO Giannis Mountzios

1/7

#ESMO23 Day2 ⚡️🔥 #CommunityOncology

1. DB04 ⬇️Her2 #bcsm

#NSCLC
2. #ALINA ALK+ Ben Solomon

3. #LIBRETTO431 RET+

4. #PAPILLON Exon20

5. #CM77T ✂️

6. #LITESPARK005 Belzutifan-RCC Toni Choueiri, MD

7. #SPOTLIGHT Cldn18.2 #gism

#OncTwitter #MedTwitter ESMO - Eur. Oncology #lcsm

1/8

En la ponencia de la Dra. Daniela Shveid Gerson Daniela Shveid Gerson en Sociedad Mexicana de Oncología, A.C. Curso de Genetica y genomica

Past/present: ADAURA in EGFR+
Present/Future: ALINA in ALK+
Future: LIBRETTO-432 in RET+ NSCLC?
Several clinical Qx
ADJ TKI if minimal residual disease? Or for those w/oMRD?
Improving worldwide inequalities
EGFR Resisters ALK Positive RETpositive EGFRm NSCLC
OncoAlert

Long-Term Survival, Prognostic Factors & Selection of Pts With Colorectal Cancer for Liver Transplant
JAMA Surgery
doi.org/10.1001/jamasu…
🔎🇳🇴RWD
👉highly selected pts with liver-only may obtain long-term OS after LTx
🚫size >5.5, CEA 80, PD on CTx, PET+ >70 cm3, >9 lesions...…

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? Which one should be utilized first? Find the answer in our latest letter to the editor, now published on Annals of Oncology. G Curigliano MD PhD Sara Tolaney annalsofoncology.org/article/S0923-…

Is neoadjuvant IO a de-escalation compared with chemo? Six patients with HER2- eBC received preop ipi/nivo/T-VEC. One pCR (pCR rate 17%), at the cost of a permanent type 1 DM, three permanent hypothyroidisms, one Addison. Half of the patients relapsed.
aacrjournals.org/cancerrescommu…

🔥Just out: The ESMO #GastricCancer Living Guideline
👉get the latest news & updates for daily decision making
ESMO - Eur. Oncology OncoAlert

📢 Neoadjuvant/adjuvant PD-1 blockade in resectable #melanoma
📍median follow-up 62 mo
📍Patients with a major pathologic response had: 5-year OS of 100% and 5-year DFS of 75%.

🪐 pubmed.ncbi.nlm.nih.gov/37414215/ ⁦Annals of Oncology⁩ ⁦ESMO - Eur. Oncology⁩ ⁦OncoAlert⁩

Today we report that removing a strain from a complex microbiome can ripple through the community in an unpredictable (& useful) way. Min Wang was the mastermind, with help from Mark Brown, Stan Hazen & crew. Cell 1/25
cell.com/cell/fulltext/…

DLL3 is the target of multiple investigational therapeutic strategies for patients with SCLC and other high-grade NE cancers. A pleasure to review state-of-the-state together with many clinical leaders of the field. jhoonline.biomedcentral.com/articles/10.11…

“The question with CDK inhibitors has been, what’s next? And what’s next is firstly a more selective and potent next generation CDK4-specific inhibitor,” says our Dr. Timothy Yap of a new generation of CDK inhibitors. fal.cn/3z7zz ASCO #ASCO23 #EndCancer

Very excited to share this final version of our paper out in nature today!
It’s the ultimate conversion of two exciting fields: epigenetics and chromosomal instability🎇

nature.com/articles/s4158…

Attendance at the plenary session 🙌🏽👏🏼✌🏼 #ASCO2023 ASCO Conquer Cancer, the ASCO Foundation Raúl Mellado-Orellana Rocala2811 OncoAlert Hem-Onc Fellows Network Journal of Clinical Oncology Oncología en Twitts